Skip to main content

Table 3 Clinicopathologic comparisons between EML4–ALK fusion-positive and fusion-negative lung adenocarcinomas

From: Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement

  Overall EML4–ALK(+) EML4–ALK(−)  
  n = 287 n = 37 (%) n = 250 (%) P value
Age Mean ± SD 48.16 ± 11.529 58.17 ± 10.03 <0.001
  Median 48 58  
  Range 24-70 25-81  
Sex Male 20(13.1) 133(86.9) 0.999
  Female 17(13.1) 113(86.9)  
  Nonavailable 0 4  
Smoking Never smoker 22(13.8) 138(86.2) 0.239
  Ever smoker 9(8.9) 92(91.1)  
  Nonavailable 6 20  
Tumor size(mm) Mean ± SD 38.42 ± 24.263 37.59 ± 16.837 0.872
  Median 32.50 35.00  
  Range 7-100 10-90  
pT status pT1 4(13.8) 25(86.2) 0.350
  pT2 14(8.3) 154(91.7)  
  pT3-T4 5(15.6) 27(84.4)  
  Nonavailable 14 44  
pN status pN0 2(2.0) 100(98.0) 0.002
  pN1 11(16.7) 55(83.3)  
  pN2-3 7(13.5) 45(86.5)  
  Nonavailable 17 50  
pTNM stages pStage I 2(2.5) 79(97.5) 0.028
  pStage II 9(12.2) 65(87.8)  
  pStage III 9(14.3) 54(85.7)  
  Nonavailable 17 52